retatrutide autoimmune disorders Weight loss with as compared to currently licenced obesity Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

If you are trying to decide between the two, our comparison page breaks down the clinical evidence for each medication

Learn more Dual GIP/GLP-1 receptor agonist with the highest average weight loss of any approved anti-obesity medication

Compounded GLP-1 drugs are custom-mixed versions of the drugs made by a pharmacy rather than FDA-approved products from the manufacturer

Submit payment for membership and medication

Emil Kongshj Larsen, the executive vice-president for international operations at Novo Nordisk, the Danish multinational which makes the drug, said: This is a landmark approval, making the UK the first country in Europe to approve Wegovy pill